alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
II 

115TH CONGRESS 

1ST SESSION S. 1079 

To require the Food and Drug Administration to revoke the approval of 

one opioid pain medication for each new opioid pain medication approved. 

IN THE SENATE OF THE UNITED STATES 

MAY 9, 2017 

Mr. MANCHIN introduced the following bill; which was read twice and referred 

to the Committee on Health, Education, Labor, and Pensions 

A BILL 

To require the Food and Drug Administration to revoke 

the approval of one opioid pain medication for each new 

opioid pain medication approved. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Protecting Americans 

5 from Dangerous Opioids Act’’. 

6 SEC. 2. FINDINGS. 

7 Congress finds as follows: 

8 (1) Opioids killed more than 33,000 people in 

9 the United States in 2015, more than any year on 


lotter on DSK5VPTVN1PROD with BILLS
2 

•S 1079 IS

1 record. Nearly half of all opioid overdose deaths in2 volve a prescription opioid. 

3 (2) According to the Centers for Disease Con4 trol, 3 out of 4 new heroin users abused prescription 

5 opioids before moving to heroin. 

6 (3) The United States makes up only 4.6 per7 cent of the world’s population, but consumes 80 per8 cent of its opioid pain medications. 

9 (4) In 2012, health care providers wrote 

10 259,000,000 prescriptions for painkillers, enough for 

11 every individual in the United States to have a bottle 

12 of pills. 

13 (5) The amount of prescription opioids sold in 

14 the United States has nearly quadrupled since 1999 

15 without a reported increase in pain. At the same 

16 time overdose deaths involving opioids have also 

17 quadrupled since 1999. 

18 SEC. 3. REQUIREMENT TO REVOKE APPROVAL. 

19 (a) IN GENERAL.—Notwithstanding any other provi20 sion of law, if the Secretary of Health and Human Serv21 ices (referred to in this section as the ‘‘Secretary’’) ap22 proves an application under subsection (b) or (j) of section 

23 505 of the Federal Food, Drug, and Cosmetic Act (21 

24 U.S.C. 355) for an opioid drug, the Secretary shall revoke 


lotter on DSK5VPTVN1PROD with BILLS
3 

•S 1079 IS

1 the approval of another opioid drug previously approved 

2 under such subsection (b) or (j). 

3 (b) CONSIDERATIONS.—In determining the drug for 

4 which the Secretary will revoke approval pursuant to sub5 section (a), the Secretary shall— 

6 (1) prioritize revocation of non-abuse deterrent 

7 formulations of opioid drugs; and 

8 (2) consider the public health impact of the 

9 opioid drug being on the market. 

Æ 


lotter on DSK5VPTVN1PROD with BILLS
# C_2019187EN.01000301.xml

| 3.6.2019 | EN | Official Journal of the European Union | C 187/3 |
| --- | --- | --- | --- |

3.6.2019

EN

Official Journal of the European Union

C 187/3

---

Judgment of the Court (Third Chamber) of 28 March 2019 — Federal Republic of Germany v European Commission

(Case C-405/16 P) (1)

(Appeal - State aid - Aid granted by certain provisions of the amended German law concerning renewable energy sources (EEG 2012) - Aid supporting renewable electricity and reduced EEG surcharge for energy-intensive users - Decision declaring the aid partially incompatible with the internal market - Concept of State aid - Advantage - State resources - Public control of resources - Measure which can be assimilated to a levy on electricity consumption)

(2019/C 187/03)

Language of the case: German

Parties

Appellant: Federal Republic of Germany (represented by T. Henze and R. Kanitz, acting as Agents, and by T. Lübbig, Rechtsanwalt)

Other party to the proceedings: European Commission (represented by K. Herrmann and T. Maxian Rusche, Agents)

Operative part of the judgment

The Court:

| 1. | Sets aside the judgment of the General Court of the European Union of 10 May 2016, Germany v Commission (T-47/15, EU:T:2016:281); |
| --- | --- |

1.

Sets aside the judgment of the General Court of the European Union of 10 May 2016, Germany v Commission (T-47/15, EU:T:2016:281);

| 2. | Annuls Commission Decision (EU) 2015/1585 of 25 November 2014 in State aid proceedings SA. 33995 (2013/C) (ex 2013/NN) [implemented by Germany for the support of renewable electricity and energy-intensive users]; |
| --- | --- |

2.

Annuls Commission Decision (EU) 2015/1585 of 25 November 2014 in State aid proceedings SA. 33995 (2013/C) (ex 2013/NN) [implemented by Germany for the support of renewable electricity and energy-intensive users];

| 3. | Orders the European Commission to pay the costs relating to both the appeal proceedings and the proceedings at first instance. |
| --- | --- |

3.

Orders the European Commission to pay the costs relating to both the appeal proceedings and the proceedings at first instance.

---

(1)  OJ C 326, 5.9.2016.

---
Case 2:04-cv-02903-JKG Document 24 Filed 03/23/10 Page 1 of 6
Case 2:04-cv-02903-JKG Document 24 Filed 03/23/10 Page 2 of 6
Case 2:04-cv-02903-JKG Document 24 Filed 03/23/10 Page 3 of 6
Case 2:04-cv-02903-JKG Document 24 Filed 03/23/10 Page 4 of 6
Case 2:04-cv-02903-JKG Document 24 Filed 03/23/10 Page 5 of 6
Case 2:04-cv-02903-JKG Document 24 Filed 03/23/10 Page 6 of 6
##### 



Exhibit 32.1
 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
  1.
    
    The Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, as amended; and
 2.
    
    The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.
 Date: May 6, 2008
    By:
    /s/ C. S. Liollio

C. S. Liollio
President and
Chief Executive Officer
## LOST COMMUNICATIONS PROCEDURES Loss of communication between the DJI Inspire 1 pilot and visual observer: The DJI 1 inspire will stop and hover at 100 feet if communications are lost. The pilot will activate the return home function for the DJI Inspire 1 if communications have been lost between the pilot and visual observer via the safest and most direct route possible. The UAS will return home at an altitude of 100 ft. or to a predetermined open area.
**Exhibit 12.2**
**FORM OF 302 CERTIFICATIONS**
I, Stefano Colombo, certify that:
 1. I have reviewed this annual report on Form 20-F of Telekom Austria;  2. Based on my knowledge, this report does not contain any untruestatement of a material fact or omit to state a material fact necessaryto make the statements made, in light of the circumstances under whichsuch statements were made, not misleading with respect to the periodcovered by this report;  3. Based on my knowledge, the financial statements, and other financialinformation included in this report, fairly present in all materialrespects the financial condition, results of operations and cash flowsof the company as of, and for, the periods presented in this report;  4. The company’s other certifying officer(s) and I are responsible forestablishing and maintaining disclosure controls and procedures (asdefined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the companyand have:
 (a) Designed such disclosure controls and procedures, or causedsuch disclosure controls and procedures to be designed under oursupervision, to ensure that material information relating to thecompany, including its consolidated subsidiaries, is made known to usby others within those entities, particularly during the period inwhich this report is being prepared;  (b) Reserved;  (c) Evaluated the effectiveness of the company’s disclosurecontrols and procedures and presented in this report our conclusionsabout the effectiveness of the disclosure controls and procedures, asof the end of the period covered by this report based on suchevaluation; and  (d) Disclosed in this report any change in the company’s internalcontrol over financial reporting that occurred during the periodcovered by the annual report that has materially affected, or isreasonable likely to materially affect, the company’s internalcontrol over financial reporting; and
 5. The company’s other certifying officer(s) and I have disclosed, basedon our most recent evaluation of internal control over financialreporting, to the company’s auditors and the audit committee of thecompany’s board of directors (or persons performing the equivalentfunctions):
 (a) All significant deficiencies and material weaknesses in thedesign or operation of internal control over financial reportingwhich are reasonably likely to adversely affect the company’s abilityto record, process, summarize and report financial information; and  (b) Any fraud, whether or not material, that involves management orother employees who have a significant role in the company’s internalcontrol over financial reporting.
Date: April 16, 2004        By: /s/ Stefano Colombo   Name: Stefano Colombo
CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002



I, J. Paul Sorbara, certify that:

1.

I have reviewed this annual report on Form 20-F of Golden Goliath Resources Ltd.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)

evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

c)

disclosed in this report any change in the registrants internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and

5.

The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions):

a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and

b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting.

Date:  February 27, 2007

|                                   |  |                     
|---------------------------------- |  | --------------------
|By:                                |  | /s/  J. Paul Sorbara
|                                   |  |                     
|J. Paul Sorbara,
President and CEO
No. 49537.

#### Protest 32333-K of C. A. Andres (New York).

Opinion by

Walker, J.

In accordance with stipulation of counsel that' the hides in question are the same in all material respects as those the subject of *Rice*v. *United States*(11 Cust. Ct.118, C. D. 807) the claim at 10 percent under paragraph 1530 was sustained.
EXHIBIT 32.1



CERTIFICATION OF CHIEF EXECUTIVE OFFICER

AND CHIEF FINANCIAL OFFICER

PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. 1350)



In connection with the Annual Report of Wells
Real Estate Fund XIII, L.P. (the Registrant) on Form 10-K for the year ended December 31, 2004, as filed with the Securities and Exchange Commission (the Report), the undersigned, Leo F. Wells, III, Chief Executive Officer of
the corporate general partner of the Registrant, and Douglas P. Williams, Chief Financial Officer of the corporate general partner of the Registrant, hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), that,
to the best of our knowledge and belief:



| | (1) |  | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and
| | --- |  | ---------------------------------------------------------------------------------------------------------------------



| | (2) |  | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
| | --- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------



|                         
|-------------------------
|/s/    LEO F. WELLS, III 
|Leo F. Wells, III        
|Chief Executive Officer  
|March 31, 2005           
|                         
|/s/  
DOUGLAS P. WILLIAMS
|Douglas P. Williams      
|Chief Financial Officer  
|March 31, 2005
No. 49953.

#### Protest 34519-K of F & M Importing Co., Inc. (Los Angeles).

Opinion by

Keefe, J.

It was stipulated that the Pecorino Sardo cheese and Provolone cheese are similar in all material respects to the merchandise passed upon in Abstracts 42146 and 42309, which records were incorporated herein. In accordance with stipulation and following the decisions cited the court held that an allowance of 2)4 percent should have been made in the weight of the cheese by the collector in computing the duty thereon to compensate for the weight of inedible coverings on the outside of the cheese. The protest was sustained to this extent.
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 18-6273

RANDY S. COOPER,

Petitioner - Appellant,

v.

PATRICK MIRANDY, Warden,

Respondent - Appellee.

Appeal from the United States District Court for the Northern District of West Virginia, 

at Wheeling. Frederick P. Stamp, Jr., Senior District Judge. (5:16-cv-00085-FPS-RWT)

Submitted: July 26, 2018 Decided: July 31, 2018

Before GREGORY, Chief Judge, FLOYD, Circuit Judge, and HAMILTON, Senior 

Circuit Judge.

Dismissed by unpublished per curiam opinion.

Randy S. Cooper, Appellant Pro Se. 

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Randy S. Cooper seeks to appeal the district court’s order accepting the 

recommendation of the magistrate judge, granting Respondent’s motion for summary 

judgment, denying Cooper’s motion to expunge information from his record, denying 

Cooper’s motion to appoint counsel, and dismissing Cooper’s 28 U.S.C. § 2254 (2012) 

petition. The order is not appealable unless a circuit justice or judge issues a certificate 

of appealability. 28 U.S.C. § 2253(c)(1)(A) (2012). A certificate of appealability will 

not issue absent “a substantial showing of the denial of a constitutional right.” 28 U.S.C. 

§ 2253(c)(2) (2012). When the district court denies relief on the merits, a prisoner 

satisfies this standard by demonstrating that reasonable jurists would find that the district 

court’s assessment of the constitutional claims is debatable or wrong. Slack v. McDaniel, 

529 U.S. 473, 484 (2000); see Miller-El v. Cockrell, 537 U.S. 322, 336-38 (2003). When 

the district court denies relief on procedural grounds, the prisoner must demonstrate both 

that the dispositive procedural ruling is debatable, and that the petition states a debatable 

claim of the denial of a constitutional right. Slack, 529 U.S. at 484-85. 

We have independently reviewed the record and conclude that Cooper has not 

made the requisite showing. Accordingly, we deny a certificate of appealability and 

dismiss the appeal. We dispense with oral argument because the facts and legal 

contentions are adequately presented in the materials before this court and argument 

would not aid the decisional process.

DISMISSED
# C_2017300EN.01002801.xml

| 11.9.2017 | EN | Official Journal of the European Union | C 300/28 |
| --- | --- | --- | --- |

11.9.2017

EN

Official Journal of the European Union

C 300/28

---

Order of the President of the Court of 5 July 2017 (request for a preliminary ruling from the Cour d’appel de Mons — Belgium) — Belgian State v Biologie Dr Antoine SPRL

(Case C-548/16) (1)

1

(2017/C 300/34)

Language of the case: French

The President of the Court has ordered that the case be removed from the register.

---

(1)  OJ C 30, 30.1.2017.

1

---
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Consumer Product Safety Commission

      ( print page 75280)    

# TIME AND DATE:

Wednesday, November 8, 2023—10 a.m.

# PLACE:

Room 420, Bethesda Towers, 4330 East West Highway, Bethesda, MD.

# STATUS:

Commission Meeting—Open to the Public.

# MATTERS TO BE CONSIDERED:

*Decisional Matter:*                         FY24 Operating Plan.                    

                        A live webcast of the meeting can be viewed at the following link:                         *https://cpsc.webex.com/​cpsc/​j.php?​MTID=​mb0c2a231d7aa95760a62dfa8f6b9d1c1.*

# CONTACT PERSON FOR MORE INFORMATION:

Alberta E. Mills, Office of the Secretary, U.S. Consumer Product Safety Commission, 4330 East West Highway, Bethesda, MD 20814, 301-504-7479 (Office) or 240-863-8938 (Cell).

Dated: October 31, 2023.

Elina Lingappa,

Paralegal Specialist.

[FR Doc. 2023-24379 Filed 10-31-23; 4:15 pm]

BILLING CODE 6355-01-P
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Heart, Lung, and Blood Institute Special Emphasis Panel; Mentored Patient Oriented Review.                    

*Date:*                         November 17, 2023.                    

*Time:*                         1:00 p.m. to 2:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, Rockledge I, 6705 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).                    

*Contact Person:*                         Fungai Chanetsa, Ph.D., MPH, Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute National Institutes of Health, 6705 Rockledge Drive, Room 206-B, Bethesda, MD 20817, (301) 402-9394,                         *fungai.chanetsa@nih.gov.*

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: November 7, 2023.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-24926 Filed 11-9-23; 8:45 am]

BILLING CODE 4140-01-P